Table 1.
Patient characteristics at baseline, after 6 months, and during follow-up according to treatment
| Variable | All (n=325) | NT (n=43) | CS (n=171) | CS+A (n=111) | P Valuea |
|---|---|---|---|---|---|
| Baseline | |||||
| Age, yr | 38.5±12.9 | 38.9±12.9 | 39.4±13.4 | 36.9±12.1 | 0.28 |
| Male sex | 242 (74.5) | 31 (72.1) | 124 (72.5) | 87 (78.4) | 0.51 |
| Histologic grade 1 | 24 (8.7) | 2 (4.6) | 14 (9.7) | 8 (9.1) | |
| Histologic grade 2 | 105 (38.2) | 21 (48.8) | 50 (34.7) | 34 (38.6) | |
| Histologic grade 3 | 146 (53.1) | 20 (46.5) | 80 (55.6) | 46 (52.3) | 0.52b |
| Serum creatinine, mg/dl | 1.45±0.7 | 1.06±0.2 | 1.52±0.7 | 1.50±0.6 | <0.001c |
| eGFR≥60 ml/min per 1.73 m2 (group 1) | 187 (57.5) | 37 (86) | 90 (52.6) | 60 (54) | |
| eGFR 30–59.9 ml/min per 1.73 m2 (group 2) | 109 (33.5) | 6 (14) | 63 (36.8) | 40 (36) | |
| eGFR<30 ml/min per 1.73 m2 (group 3) | 29 (8.9) | 0 | 18 (10.5) | 11 (10) | 0.002d |
| RAS blockers | 164 (50.5) | 5 (11.6) | 92 (53.8) | 67 (60.4) | <0.001e |
| Systolic BP, mmHg | 132.9±16.6 | 133.4±20.7 | 133.2±16.0 | 132.2±16.0 | 0.63 |
| Diastolic BP, mmHg | 82.7±10.4 | 83.4±12.3 | 82.8±10.1 | 82.2±10.1 | 0.79 |
| Proteinuria, g/d | 2.35±1.5 | 1.988±0.7 | 2.2±1.0 | 2.876±2.1 | <0.001f |
| 1.0 to <2.0 g/d | 183 (56.3) | 30 (69.8) | 98 (57.3) | 55 (49.5) | |
| 2.0 to <3.0 g/d | 85 (25.1) | 11 (25.6) | 47 (27.5) | 27 (24.3 | |
| ≥ 3.0 g/d | 57 (17.5) | 2 (15.2) | 26 (15.2) | 29 (26.1) | 0.02 |
| After 6 mo | |||||
| Proteinuria, g/dg | 0.9 (0.5–1.6) | 1.7 (1.1–2.4) | 0.8 (0.4–1.2) | 1.0 (0.5–1.7) | <0.001h |
| ≤0.3 g/d | 36 (11.6) | 0 (0) | 21 (12.9) | 15 14.4) | |
| >0.3 to <1.0 g/d | 125 (40.3) | 9 (20.9) | 78 (47.8) | 38 (36.5) | |
| 1.0 to <2.0 g/d | 94 (30.3) | 16 (37.2) | 47 (28.8) | 31 (29.8) | |
| 2.0 to <3.0 g/d | 32 (10.3) | 10 (23.3) | 12 (7.4) | 10 (9.6) | |
| ≥3.0 g/d | 23 (7.4) | 8 (18.6) | 5 (3.1) | 10 (9.6) | <0.001b,i |
| Follow-up | |||||
| RAS blockers | 259 (79.7) | 18 (41.9) | 140 (81.9) | 101 (91.0) | <0.001j |
| Proteinuria, g/dg | 0.7 (0.4–1.3) | 1.4 (0.8–2.4) | 0.6 (0.3–1.1) | 0.7 (0.3–1.7) | <0.001k |
| ≤0.3 g/d (TAp1) | 58 (17.8) | 1 (2.3) | 35 (20.5) | 22 19.8) | |
| >0.3 to <1.0 g/d (TAp2) | 144 (44.3) | 12 (27.9) | 80 (46.8) | 52 (46.8) | |
| 1.0 to <2.0 g/d (TAp3) | 77 (23.7) | 14 (32.6) | 44 (25.7) | 19 (17.1) | |
| 2.0 to <3.0 g/d (TAp4) | 22 (6.8) | 7 (16.3) | 9 (5.3) | 6 (5.4) | |
| ≥3.0 g/d (TAp5) | 24 (7.4) | 9 (20.9) | 3 (1.7) | 12 (10.8) | <0.001b,l |
Unless otherwise noted, data are expressed as n (%) for qualitative variables and mean±SD) for quantitative variables. NT, no treatment; CS, corticosteroids; CS+A: corticosteroids plus azathioprine; RAS, renin-angiotensin system; TAp, time-average proteinuria.
P value refers to differences among three treatment groups.
P value for differences also among all proteinuria groups.
NT versus CS and NT versus CS+A: P<0.001; CS versus CS+A: P=0.98.
NT versus CS: P=0.001; NT versus CS+A: P=0.001; CS versus CS+A: P=0.97.
NT versus CS and NT versus CS+A: P<0.001; CS versus CS+A: P=0.28.
For all comparisons: P<0.001.
Values are expressed as median (interquartile range).
For all comparisons: P<0.001.
NT versus CS and NT versus CS+A: P<0.001; CS versus CS+A: P=0.13.
NT versus CS and NT versus CS+A: P<0.001; CS versus CS+A: P=0.03.
NT versus CS and NT versus CS+A: P<0.001; CS versus CS+A: P=0.002.
NT versus CS and NT versus CS+A: P<0.001; CS versus CS+A: P=0.01.